X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Divis Laboratories with Cipla - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DIVIS LABORATORIES vs CIPLA - Comparison Results

DIVIS LABORATORIES    Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DIVIS LABORATORIES CIPLA DIVIS LABORATORIES/
CIPLA
 
P/E (TTM) x 31.3 44.3 70.8% View Chart
P/BV x 5.4 3.9 140.4% View Chart
Dividend Yield % 0.9 0.3 274.8%  

Financials

 DIVIS LABORATORIES   CIPLA
EQUITY SHARE DATA
    DIVIS LABORATORIES
Mar-17
CIPLA
Mar-17
DIVIS LABORATORIES/
CIPLA
5-Yr Chart
Click to enlarge
High Rs1,222622 196.5%   
Low Rs784458 171.1%   
Sales per share (Unadj.) Rs153.1181.9 84.2%  
Earnings per share (Unadj.) Rs39.912.9 310.4%  
Cash flow per share (Unadj.) Rs44.629.3 152.1%  
Dividends per share (Unadj.) Rs10.002.00 500.0%  
Dividend yield (eoy) %1.00.4 269.2%  
Book value per share (Unadj.) Rs201.8155.7 129.6%  
Shares outstanding (eoy) m265.47804.51 33.0%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x6.63.0 220.6%   
Avg P/E ratio x25.142.0 59.8%  
P/CF ratio (eoy) x22.518.4 122.1%  
Price / Book Value ratio x5.03.5 143.3%  
Dividend payout %25.015.5 161.1%   
Avg Mkt Cap Rs m266,266434,516 61.3%   
No. of employees `0009.723.0 42.2%   
Total wages/salary Rs m4,68726,338 17.8%   
Avg. sales/employee Rs Th4,175.06,349.1 65.8%   
Avg. wages/employee Rs Th481.51,143.0 42.1%   
Avg. net profit/employee Rs Th1,089.3449.3 242.4%   
INCOME DATA
Net Sales Rs m40,643146,302 27.8%  
Other income Rs m7492,287 32.7%   
Total revenues Rs m41,392148,589 27.9%   
Gross profit Rs m14,46024,758 58.4%  
Depreciation Rs m1,23313,229 9.3%   
Interest Rs m231,594 1.4%   
Profit before tax Rs m13,95312,222 114.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-70 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3,3491,798 186.3%   
Profit after tax Rs m10,60410,354 102.4%  
Gross profit margin %35.616.9 210.2%  
Effective tax rate %24.014.7 163.2%   
Net profit margin %26.17.1 368.7%  
BALANCE SHEET DATA
Current assets Rs m40,10587,370 45.9%   
Current liabilities Rs m6,59533,081 19.9%   
Net working cap to sales %82.537.1 222.2%  
Current ratio x6.12.6 230.3%  
Inventory Days Days11987 136.3%  
Debtors Days Days8162 129.5%  
Net fixed assets Rs m19,995111,567 17.9%   
Share capital Rs m5311,609 33.0%   
"Free" reserves Rs m53,043123,645 42.9%   
Net worth Rs m53,574125,254 42.8%   
Long term debt Rs m036,454 0.0%   
Total assets Rs m61,585209,532 29.4%  
Interest coverage x618.48.7 7,134.1%   
Debt to equity ratio x00.3 0.0%  
Sales to assets ratio x0.70.7 94.5%   
Return on assets %17.35.7 302.6%  
Return on equity %19.88.3 239.4%  
Return on capital %26.18.5 306.9%  
Exports to sales %034.2 0.0%   
Imports to sales %25.28.3 302.6%   
Exports (fob) Rs mNA50,050 0.0%   
Imports (cif) Rs m10,25912,203 84.1%   
Fx inflow Rs m35,38451,066 69.3%   
Fx outflow Rs m10,39917,678 58.8%   
Net fx Rs m24,98533,388 74.8%   
CASH FLOW
From Operations Rs m11,49323,824 48.2%  
From Investments Rs m-11,372-13,127 86.6%  
From Financial Activity Rs m-93-13,239 0.7%  
Net Cashflow Rs m28-2,478 -1.1%  

Share Holding

Indian Promoters % 52.0 16.0 325.0%  
Foreign collaborators % 0.0 20.8 -  
Indian inst/Mut Fund % 11.8 12.2 96.7%  
FIIs % 19.0 23.7 80.2%  
ADR/GDR % 0.0 1.1 -  
Free float % 17.2 26.2 65.6%  
Shareholders   31,796 161,166 19.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DIVIS LABORATORIES With:   AUROBINDO PHARMA  MERCK LTD  GSK PHARMA  FULFORD INDIA  ORCHID PHARMA LTD  

Compare DIVIS LABORATORIES With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Of Global Markets Hitting Record Highs and Top Stocks in Action During the Week(RoundUp)

Global stock markets ended the week on a positive note. Benchmark indices in US grew by 1% during the week. The Down Jones Industrial Average topped the 26,000.

Related Views on News

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Cipla: Extraordinary Income Boosts Net Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

Proceeds from the sale of the South African animal business bolstered Cipla's net profits for the quarter.

Cipla: Operating Margins Improve (Quarterly Results Update - Detailed)

Mar 8, 2017

Cipla has announced its results for the December quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DIVIS LABORATORIES SHARE PRICE


Jan 19, 2018 (Close)

TRACK DIVIS LABORATORIES

  • Track your investment in DIVIS LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DIVIS LABORATORIES

DIVIS LABORATORIES 5-YR ANALYSIS

COMPARE DIVIS LABORATORIES WITH

MARKET STATS